

Press release

Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools

Chicago and Munich — October 20, 2020 — Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.

ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry's growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.

"Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers," said Dr. Marion Jung, CEO of ChromoTek. "It is exciting to be working together with a company that shares our values in reproducibility and quality for the benefit of research and beyond."

Dr. Jason Li, CEO of Proteintech, said, "This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we'll also deeply impact translational science and therapeutic applications."

ChromoTek GmbH is located in the Biotechnology Innovation and Start-up Center in Martinsried near Munich and has become the leading manufacturer of alpaca nanobodies. The biotech start-up had the vision to improve, accelerate and simplify the research of its customers around the world. "I am very proud that Dr. Marion Jung, Managing Director of ChromoTek GmbH, has achieved this goal and will now serve a global market from Bavaria through the cooperation with Proteintech", said Dr. Peter Hanns Zobel, Managing Director of the IZB.

About Proteintech Group

Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive

and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com.

About ChromoTek

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried (Germany) near Munich and Islandia (NY, USA). To learn more about ChromoTek, please visit www.chromotek.com

Press contact ChromoTek

Proteintech Group, Inc.

Katie Bellows

katie@ptglab.com

About the Innovation and Start-up Center Biotechnology (IZB):

The company IZB mbH, founded in 1995, is the operating company of the Innovation and Start-Up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into one of the top ten renowned biotechnology centers in the world. More than 50 biotech companies with more than 600 employees are currently located on an area covering 26,000 m². This is where work focuses on developing drugs against the most severe diseases such as cancer, Alzheimer's disease and various autoimmune diseases – and there are already many successes. At the IZB Freising-Weihenstephan – 15 minutes from the airport – scientists are working on developments in the field of life sciences. An essential criterion for the success of the IZBs is the proximity to top research on the Martinsried/Grosshadern Campus. The new infrastructure measures, such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Chemistry College Elhardt, the two kindergartens BioKids and BioKids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker, have become decisive location factors. Successful companies that have emerged from the IZB include, for example, Medigene AG, Morphosys AG, Micromet GmbH (now Amgen AG), Octopharma GmbH and Corimmun (today Janssen-Cilag). More information at www.izb-online.de

Press contact IZB:

Susanne Simon, Head of Public Relations

Innovation and Start-ups Center Biotechnology

Am Klopferspitz 19, D-82152 Planegg-Martinsried near Munich

Tel.: +49 (0)89/55 279 48-17, Fax: +49 (0)89/55 279 48-29

E-Mail: simon@izb-online.de

Website: www.izb-online.de




Foto (f.l.t.r.) ChromoTek- und Proteintech-Team

Dr. Katrin Schmidthals, VP Finance & Administration ChromoTek, Jeff Lee, COO Proteintech Group, Dr. Marion Jung, CEO ChromoTek, Dr. Jason Li, CEO Proteintech Group



Foto ChromoTek- und Proteintech-Team

Back row: f.l.t.r.: Jeff Lee, COO Proteintech Group, Dr. Felix Hartlepp, VP R&D ChromoTek, Kier Wilkinson, Managing Director Europe Proteintech Group, Dr. Klaus Herick, VP Marketing & Sales, ChromoTek

Front row f.l.t.r.: Katie Bellows, Head of US Branch Proteintech Group; Deepa Shankar, CSO Proteintech Group; Dr. Frank Schestag, Sales Director Europe Proteintech Group; Dr. Marion Jung, CEO ChromoTek; Dr. Katrin Schmidthals, VP Finance & Administration ChromoTek; Dr. Jason Li, CEO Proteintech Group